J1323 Injection, elranatamab-bcmm, 1 milligrams
Also known as: Elrexfio, elranatamab
Elranatamab-bcmm injection supplied in 1 milligram units, a B-cell maturation antigen bispecific monoclonal antibody for multiple myeloma.
In Plain Language
Cancer treatment medicine
Clinical Context
Used for treatment of relapsed or refractory multiple myeloma with dual engagement of B-cell maturation antigen and CD3.
RVU Information
CPT J1323 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J1323?
CPT J1323 (Injection, elranatamab-bcmm, 1 milligrams) is a J Codes (Drugs) code. Elranatamab-bcmm injection supplied in 1 milligram units, a B-cell maturation antigen bispecific monoclonal antibody for multiple myeloma.
How is J1323 administered?
CPT J1323 is administered by a healthcare provider, typically via injection or infusion. Used for treatment of relapsed or refractory multiple myeloma with dual engagement of B-cell maturation antigen and CD3. It is used by Oncology, Hematology, Internal Medicine.
When is CPT J1323 used?
Used for treatment of relapsed or refractory multiple myeloma with dual engagement of B-cell maturation antigen and CD3.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.